ATE230023T1 - Beeinflussung der zelladhäsion durch oligonukleotide - Google Patents

Beeinflussung der zelladhäsion durch oligonukleotide

Info

Publication number
ATE230023T1
ATE230023T1 AT91914455T AT91914455T ATE230023T1 AT E230023 T1 ATE230023 T1 AT E230023T1 AT 91914455 T AT91914455 T AT 91914455T AT 91914455 T AT91914455 T AT 91914455T AT E230023 T1 ATE230023 T1 AT E230023T1
Authority
AT
Austria
Prior art keywords
cell adhesion
oligonucleotide
oligonucleotides
treatment
methods
Prior art date
Application number
AT91914455T
Other languages
English (en)
Inventor
Clarence Frank Bennett
Christopher K Mirabelli
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE230023T1 publication Critical patent/ATE230023T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Storage Device Security (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91914455T 1990-08-14 1991-07-23 Beeinflussung der zelladhäsion durch oligonukleotide ATE230023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56728690A 1990-08-14 1990-08-14
PCT/US1991/005209 WO1992003139A1 (en) 1990-08-14 1991-07-23 Oligonucleotide modulation of cell adhesion

Publications (1)

Publication Number Publication Date
ATE230023T1 true ATE230023T1 (de) 2003-01-15

Family

ID=24266532

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91914455T ATE230023T1 (de) 1990-08-14 1991-07-23 Beeinflussung der zelladhäsion durch oligonukleotide

Country Status (14)

Country Link
EP (1) EP0544716B1 (de)
JP (1) JP2732544B2 (de)
KR (1) KR960009261B1 (de)
AT (1) ATE230023T1 (de)
AU (1) AU641539B2 (de)
BR (2) BR9106746A (de)
CA (1) CA2089563C (de)
DE (1) DE69133180T2 (de)
DK (1) DK0544716T3 (de)
ES (1) ES2188581T3 (de)
FI (1) FI930627A0 (de)
HU (1) HU217107B (de)
NO (1) NO930513L (de)
WO (1) WO1992003139A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
BR9307844A (pt) * 1992-01-31 1996-01-09 Univ California Processo para a formaçao de uma célula livre de antigenes para transplante célula livre de antigenes para transplante oligonucleotideo capaz de ligaçao a uma sequéncia nucleotidea antigene para transplante oligonucleotideo para utilizaçao na preparaçao de uma composiçao para o tratamento de células alvo orgao doador universal e processo para o tratamento de um individuo com uma doença autoimune
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
HUT69922A (en) * 1992-09-02 1995-09-28 Isis Pharmaceuticals Inc Oligonucleotide modification of cell adhesion
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
JPH08113591A (ja) * 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk オリゴヌクレオチド及びこれを有効成分とする制癌剤
JPH10510433A (ja) * 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
CN104531843A (zh) * 2014-12-04 2015-04-22 杭州中翰金诺生物信息技术有限公司 肝癌诊断标志物黑素瘤细胞黏附分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353290A4 (en) * 1988-01-21 1990-09-05 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
JP2732544B2 (ja) 1998-03-30
HUT68322A (en) 1995-06-28
HU217107B (hu) 1999-11-29
WO1992003139A1 (en) 1992-03-05
HU9300373D0 (en) 1993-05-28
CA2089563C (en) 2004-04-06
BR9106746A (pt) 1993-07-20
EP0544716B1 (de) 2002-12-18
KR960009261B1 (en) 1996-07-16
EP0544716A1 (de) 1993-06-09
NO930513L (no) 1993-04-01
AU641539B2 (en) 1993-09-23
JPH05508998A (ja) 1993-12-16
FI930627A7 (fi) 1993-02-12
DE69133180D1 (de) 2003-01-30
AU8313091A (en) 1992-03-17
DE69133180T2 (de) 2003-07-24
KR930701180A (ko) 1993-06-11
DK0544716T3 (da) 2003-03-17
BR1100617A (pt) 2000-06-13
CA2089563A1 (en) 1992-02-15
ES2188581T3 (es) 2003-07-01
NO930513D0 (no) 1993-02-12
EP0544716A4 (en) 1994-09-14
FI930627A0 (fi) 1993-02-12

Similar Documents

Publication Publication Date Title
DE69332668D1 (de) Beeinflussing der zelladhäsie durch oligonukleotide
EP0527818A4 (en) Oligonucleotide modulation of arachidonic acid metabolism
ATE244506T1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DE69331467D1 (de) Oligonukleotide modulation von protein kinase c
DE69133180D1 (de) Beeinflussung der zelladhäsion durch oligonukleotide
EP0714449A4 (de) Oligonukleotid modulation von protein kinase
ATE318273T1 (de) Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
EP1185696A4 (de) Modifikation der expression der menschlichen proteinkinase c-delta mit hilfe von antisense-oligonukleotiden
Pizzuti et al. Detection of β-nerve growth factor mRNA in the human fetal brain
Bennett et al. Oligonucleotide modulation of cell adhesion
NO924140L (no) Oligonukleotidmodulering av arachidonsyre-metabolisme
TH39471A (th) อะพอพโทซิสที่ควบคุมโดยตนเองของเซลล์ที่เกี่ยวข้องกับการอักเสบ โดยการรักษาระดับจีน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0544716

Country of ref document: EP

EELA Cancelled due to lapse of time